AstraZeneca announced that it has completed the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US.
The agreement covers seven established medicines – Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest).
As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company’s financial statements.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
UK/Global
Neil Burrows
+44 203 749 5637
Vanessa Rhodes
+44 203 749 5736
Karen Birmingham
+44 203 749 5634
Rob Skelding
+44 203 749 5821
Sweden
Jacob Lund
+46 8 553 260 20
US
Michele Meixell
+1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Nick Stone
Respiratory & Autoimmunity
+44 203 749 5716
Henry Wheeler
Oncology
+44 203 749 5797
Christer Gruvris
Infection & Neuroscience
+44 203 749 5711
US
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Mitch Chan
Oncology
+1 240 477 3771
